Budigalimab (Not yet branded)

Immunotherapy

Experimental

Not available IV 2 Clinical Trials

PD-1

Description

Budigalimab is a monoclonal antibody immunotherapy agent that targets the PD-1/PD-L1 checkpoint pathway. This agent has been evaluated in early-phase clinical studies for various solid tumors including colorectal cancer, particularly in tumor-agnostic settings where treatment selection is based on specific biomarkers rather than tumor location. In colorectal cancer, budigalimab is being explored for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors.

Mechanism of Action

Budigalimab functions as a PD-1 receptor antagonist, blocking the interaction between PD-1 on T-cells and PD-L1 on tumor cells. By inhibiting this immune checkpoint pathway, the drug prevents tumor cells from evading immune surveillance and allows the patient's immune system to recognize and attack cancer cells more effectively.

Molecular Targets

PD-1

Side Effects

Fatigue Skin rash Diarrhea Decreased appetite Nausea Pyrexia Pruritus Hypothyroidism

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05005403 Phase 1

Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalima

United States, Canada, Israel, Japan, South Korea, Taiwan

NCT03821935 Phase 1

Active, not recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Japan

Quick Info

Brand Name	Not yet branded
Category	Immunotherapy
Status	Experimental
EMA Status	Experimental
Spain Access	Not available
Administration	IV
Clinical Trials	2

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.